Corebridge Financial Inc. Decreases Position in IQVIA Holdings Inc. (NYSE:IQV)

Corebridge Financial Inc. lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 5.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,116 shares of the medical research company’s stock after selling 2,601 shares during the quarter. Corebridge Financial Inc.’s holdings in IQVIA were worth $8,080,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Intech Investment Management LLC acquired a new position in IQVIA during the third quarter worth about $223,000. Algert Global LLC acquired a new position in shares of IQVIA during the 3rd quarter worth approximately $514,000. Larson Financial Group LLC lifted its stake in IQVIA by 745.1% in the 3rd quarter. Larson Financial Group LLC now owns 431 shares of the medical research company’s stock valued at $102,000 after buying an additional 380 shares in the last quarter. Fisher Asset Management LLC grew its holdings in IQVIA by 4.8% during the 3rd quarter. Fisher Asset Management LLC now owns 7,398 shares of the medical research company’s stock valued at $1,753,000 after buying an additional 341 shares during the last quarter. Finally, Private Trust Co. NA increased its position in IQVIA by 10.7% during the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after buying an additional 47 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the topic of a number of analyst reports. JPMorgan Chase & Co. decreased their price objective on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Robert W. Baird lowered their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. Truist Financial reissued a “buy” rating and set a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Finally, Barclays cut their price target on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Trading Down 0.3 %

Shares of IQV stock opened at $179.40 on Friday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a fifty-two week low of $176.74 and a fifty-two week high of $253.84. The firm’s 50 day moving average price is $193.55 and its two-hundred day moving average price is $206.91. The stock has a market cap of $31.63 billion, a price-to-earnings ratio of 23.92, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.